SIPPET: Pre-and Post-Study Hemophilia Meeting Ongoing evaluation of the 5-year study

3 Yeni

Active Substance



Organized by Er-Kim İlaç A.Ş., the series of meeting named “SIPPET: Pre-and Post-Study Hemophilia” is continuing.

While the first of the meeting series titled“SIPPET: Pre-and Post-Study Hemophilia”was performed in İzmir, the second was in Adana and the third was in Ankara with the participation of pediatric hematologists.

In the meetings performed under the presidency of Prof. Dr. Kaan Kavaklı, lecturer in Ege University and Prof. Dr. Bülent Antmen from Adana Acıbadem Hospital, the results of the 5-years SIPPET (Survey of Inhibitors in Plasma Product Exposed Toddlers) Study comparing plasma derivative factor VIII (pdFVIII) products with recombinant factor VIII (rFVIII) preparations, and its influence on the current hemophilia treatments were discussed in depth.

 While in Adana Meeting Prof. Dr. İlgen Şaşmaz presented France Hemophilia guidelines and Dr. Defne Ay Tuncel the British hemophilia guidelines, in Ankara Meeting, Doç. Dr. Selin Aytaç presented the studies carried out using the guidelines.

In the second part of the meetings, a platform was generated with the active participation of attendees on what kind of approach would be shown in future in hemophilia treatment in the light of the SIPPET Study information presented in American Society of Hematology (ASH) Congress in December 2015 and in the European Association for Hemophilia and Allied Disorders (EAHAD) Congress in February 2016.

The issue of the need of reevaluation of treatment approaches and guidelines by specialty associations regarding the “inhibitor issue”, the most important issue in the field of hemophilia treatment as the result of the SIPPET Study, was discussed by the physicians participated in the meeting.

SIPPET – Survey of Inhibitors in Plasma Product Exposed Toddlers

In the SIPPET Study that continued for over five years with participation of 42 centers from 15 countries with three centers from Turkey, severe hemophilia patients who had not previously been treated with factor III (PUPs: Previously Untreated Patients) were included. According to the results obtained from the SIPPET Study in which the risk of inhibitor development, currently the most important issue in hemophilia, was reviewed, it was shown that the rate of inhibitor development in patients using recombinant FVIII was higher compared to those using plasma derivative FVIII.